Business
Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to Drive Growth in Two Key Business Areas
The company reiterates full year 2022 guidance SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a
About this update from Adaptive Biotechnologies Corporation
[{"type":"text","content":"The company reiterates full year 2022 guidance\nSEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of Tycho Peterson as chief financial officer (CFO). Mr. Peterson brings several decades of financial leadership and experience within the life science and diagnostic industries. “Tycho has been a leader in this space over the last two decades, during which disruptive technologies such as genomic sequencing and artificial intelligence have driven a complete paradigm shift in diagnostics and precision medicine,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “As the space continues to transform toward the data-driven development of diagnostics and therapeutics, Tycho’s intimate knowledge of the technologies and what it takes to realize their potential will be instrumental in our mission to power the age of immune medicine.” Mr. Peterson most recently held a 23-year tenure with J.P. Morgan Chase & Co., where he served as managing director, life science tools and diagnostics in the health care group. “I have followed Adaptive from the very early days, and it has been clear from the beginning that the company is well-poised to transform medicine through unique insights from the adaptive immune system,” said Mr. Peterson. “I am thrilled to take this next step in my career to help realize the company’s potential to bring novel immune-driven diagnostic and therapeutic products to clinicians and patients.” Mr. Peterson joins Adaptive as the company undergoes a reorganization into two newly created business areas – Minimal Residual Disease (MRD) and Immune Medicine. Strategic Reorganization To drive future growth, Adaptive will be organized around two distinct business areas: MRD and Immune Medicine. Adaptive’s MRD business is comprised of its clonoSEQ® diagnostic test offered to clinicians and the clonoSEQ assay offered to its pharmaceutical partners to support drug development and approvals. clonoSEQ is the first and only FDA-cleared assay for MRD in chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (ALL). This reorgani...